CD4 and breast cancer: In the IMvigor 210 trial, which examined the response of metastatic BC patients to the PD-L1 inhibitor atezolizumab, the presence of cytotoxic CD4+ T cells in inflamed TMEs was linked to a higher likelihood of response to therapy.